United Therapeutics (UTHR) is back in focus after the FDA accepted its New Drug Application for ralinepag in pulmonary arterial hypertension and set a June 24, 2027 target action date for the review.
At a recent share price of US$518.53, United Therapeutics has seen a 1-year total shareholder return of 67.69% and a 5-year total shareholder return of 141.31%. The 90-day share price return is down 9.15% as the market absorbs the NDA acceptance for ralinepag and other pipeline milestones such as full enrollment of the TETON PPF trial for nebulized Tyvaso.
Compare United Therapeutics' regulatory momentum with other potential high quality opportunities by scanning our curated 49 high quality undervalued stocks across the market.
After a 68% total return over the past year and a sharp swing around the ralinepag news, investors in United Therapeutics now face a simple test: Is most of the value already in the price, or not yet?
Most Popular Narrative: 22.1% Undervalued
At a last close of $518.53 versus a narrative fair value of $665.23, the most followed view sees meaningful upside potential for United Therapeutics and ties that directly to its pulmonary and organ platform pipeline.
The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.
Read the complete narrative. Read the complete narrative.
Want to know what turns that pipeline into the $665.23 fair value number. The narrative leans on stronger revenue trajectories, firm margins, and a lower future earnings multiple than today. Curious how those ingredients interact to support a higher valuation than the current $518.53 price.
Result: Fair Value of $665.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, United Therapeutics still faces key risks, including potential setbacks in TETON or ADVANCE OUTCOMES trial results and ongoing pressure from branded and generic competitors in its PAH therapies.
Find out about the key risks to this United Therapeutics narrative.
Next Steps
With sentiment in this United Therapeutics piece skewed toward opportunity, it makes sense to check the underlying data yourself and move quickly while opinions are forming. To see what those potential bright spots look like in detail, review the 5 key rewards.
Looking for more investment ideas beyond United Therapeutics?
If you stop with United Therapeutics, you miss a wider set of potential ideas. Use the screener to quickly surface other stocks that might fit your approach.
- Spot opportunities that the crowd may be overlooking by scanning a focused 18 high quality undiscovered gems that highlights companies with strong underlying fundamentals.
- Strengthen your portfolio foundation by reviewing a list of solid balance sheet and fundamentals (51 results) that can help you concentrate on businesses with healthier financial positions.
- Dial down overall risk by filtering for a 74 resilient stocks with low risk scores so you can spend more time comparing quality rather than worrying about hidden red flags.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com